OR WAIT null SECS
September 04, 2022
With this approval, about 300 children between 12 months and 24 months will be eligible for treatment with Orkambi.
August 03, 2022
Coherus’ Cimerli has been approved to be interchangeable for all five indications, including age-related macular degeneration and diabetic retinopathy. It will be available in early October 2022.
June 09, 2022
Two studies conducted by AllianceRx Walgreens Prime call attention to the importance of adherence for reducing risk of negative health outcomes and financial costs.
May 24, 2022
Tyvaso DPI is a dry inhalation powder and new inhalation device to treat patients with pulmonary arterial hypertension, a life-threatening disease. It is expected to be available in June 2022.
March 16, 2022
Called Breyna, this drug-device combination generic product is a metered-dose inhaler, which contains both budesonide and formoterol.
March 15, 2022
The FDA has asked for clinical data for Fasenra, which is being reviewed as a treatment for chronic rhinosinusitis with nasal polyps.
October 22, 2021
Developed by Regeneron Pharmaceuticals and Sanofi, Dupixent reduced severe asthma attacks and improved lung function in children 6 to 11 years.
October 18, 2021
The agency cited an open inspection issue at a facility that performs analytical testing of drug substance.
July 08, 2021
The agency also granted tezepelumab priority review with a PDUFA date sometime in the first quarter of 2022.
June 10, 2019
The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.
